CN114145458A - Application of palmitic acid glyceride in preparing composition for improving or promoting magnesium absorption of human body - Google Patents
Application of palmitic acid glyceride in preparing composition for improving or promoting magnesium absorption of human body Download PDFInfo
- Publication number
- CN114145458A CN114145458A CN202111431476.7A CN202111431476A CN114145458A CN 114145458 A CN114145458 A CN 114145458A CN 202111431476 A CN202111431476 A CN 202111431476A CN 114145458 A CN114145458 A CN 114145458A
- Authority
- CN
- China
- Prior art keywords
- palmitic acid
- acid
- content
- composition
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C19/00—Cheese; Cheese preparations; Making thereof
- A23C19/06—Treating cheese curd after whey separation; Products obtained thereby
- A23C19/09—Other cheese preparations; Mixtures of cheese with other foodstuffs
- A23C19/093—Addition of non-milk fats or non-milk proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/04—Whey; Whey preparations containing non-milk components as source of fats or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/06—Mixtures of whey with milk products or milk components
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/08—Whey; Whey preparations containing other organic additives, e.g. vegetable or animal products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/10—Whey; Whey preparations containing inorganic additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1315—Non-milk proteins or fats; Seeds, pulses, cereals or soja; Fatty acids, phospholipids, mono- or diglycerides or derivatives therefrom; Egg products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1528—Fatty acids; Mono- or diglycerides; Petroleum jelly; Paraffine; Phospholipids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Mycology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Dairy Products (AREA)
Abstract
The invention provides application of palmitic acid glyceride in preparing a composition for improving or promoting magnesium absorption of a human body, and particularly provides application of the palmitic acid glyceride in preparing a composition for improving or promoting magnesium absorption of a human body, wherein calculated by palmitic acid, Sn-2 palmitic acid in the palmitic acid glyceride accounts for more than 35%, preferably more than 40%, and more preferably more than 46% of all palmitic acid contents. The invention also provides the use of a combination of glyceryl palmitate with alpha-lactalbumin and/or beta-casein in the manufacture of a composition for improving or promoting magnesium absorption in infants and young children. The palmitic acid glyceride and the combination of the palmitic acid glyceride and the alpha-lactalbumin and/or the beta-casein in the invention are helpful for promoting or improving the absorption of magnesium element in human bodies, and are suitable for people at various ages, especially for infants.
Description
Technical Field
The invention relates to a new application of palmitic acid glyceride, in particular to an application of the palmitic acid glyceride in preparing a composition for improving or promoting magnesium absorption of a human body.
Background
Breast milk fat provides 45% -60% of energy for early growth of infants, and more than 98% of breast milk fat is triglyceride. The positions of different fatty acids in the breast milk esterified with glycerol are different; wherein unsaturated fatty acids such as linoleic acid and alpha-linolenic acid in the breast milk are more than 1 site and 3 sites of the triglyceride; long chain saturated fatty acids such as palmitic acid in breast milk are mainly located at the 2-position, and thus formed palmitic acid triglyceride is called Sn-2 palmitic acid triglyceride. In the digestive tract, the lipolytic enzymes of the infant's stomach act primarily on the 1-and 3-ester bonds of triglycerides, so that unsaturated fatty acids are first freed and then degraded and absorbed in the duodenum along with Sn-2 palmitic acid monoglyceride. However, the common infant formula powder contains palm oil, most of long-chain saturated fatty acids of the palm oil are esterified on ester bonds at the 1-position and the 3-position of triglyceride, and the palm oil is easy to combine with calcium ions after hydrolysis to form calcium soap, so that the absorption of fat and mineral substances is reduced, and the calcium soap which is difficult to absorb can also cause hard excrement to cause difficult defecation.
The existing research shows that the infant can improve the absorptivity of the infant intestinal tract to palmitic acid and calcium and soften the excrement of the infant by eating the formula milk powder containing Sn-2 palmitic acid glyceride. By eating the formula powder, the absorption of fat and calcium of the infant can be improved, the constipation and crying conditions of the infant can be improved, and the quantity of beneficial bacteria in the intestinal tract of the infant can be increased. The intestinal beneficial bacteria can prevent pathogenic bacteria from colonizing in infant intestinal, reduce incidence of infant diarrhea, and produce B vitamins and short chain fatty acids, which is beneficial to development of infant immune system.
The content of magnesium in bones is second to that of calcium and phosphorus, is an essential element for maintaining the structure and the function of bone cells, and has the functions of maintaining and promoting the growth of bones and teeth. There is no research report on whether Sn-2 palmitic acid glyceride can promote the absorption of magnesium by human body.
Disclosure of Invention
The invention aims to provide a novel application of the palmitic acid glyceride in preparing a composition for improving or promoting the absorption of magnesium element by a human body.
The content of magnesium in bones is second to that of calcium and phosphorus, is an essential element for maintaining the structure and the function of bone cells, and has the functions of maintaining and promoting the growth of bones and teeth. The inventor of the invention finds that the palmitic acid glyceride can promote the absorption and utilization of magnesium element for infants.
Thus, in one aspect, the present invention provides the use of a palmitic acid glyceride, wherein the content of Sn-2 palmitic acid in the palmitic acid glyceride is 35% or more, preferably 40% or more, more preferably 46% or more, of the total palmitic acid content, calculated as palmitic acid, in the manufacture of a composition for improving or promoting the absorption of magnesium by the human body.
The ratio of the Sn-2-position palmitic acid in the palmitic acid glyceride to the total palmitic acid content is the ratio of the Sn-2-position palmitic acid in the palmitic acid glyceride as the raw material. Since some palmitic acid is also brought by raw milk, anhydrous cream, vegetable oil, and the like, in a composition such as food, milk powder, and the like to which palmitic acid glyceride is added, the ratio of Sn-2-position palmitic acid in the content of all palmitic acid in the composition may be lower than the ratio of Sn-2-position palmitic acid in palmitic acid glyceride as a raw material.
According to a specific embodiment of the present invention, preferably, the content of Sn-2 palmitic acid in palmitic acid glyceride is 52% or more, more preferably 60% or more, of the total palmitic acid content.
According to a specific embodiment of the present invention, the Sn-2 glyceryl palmitate comprises one or more of a Sn-2 position triglyceride palmitate, a Sn-2 position diglyceride palmitate and a Sn-2 position monoglyceride palmitate;
wherein, any fatty acid can be connected to the Sn-1 position and/or the Sn-3 position on the glyceryl in the Sn-2 palmitic acid diglyceride and the Sn-2 palmitic acid triglyceride, and the fatty acid comprises, but is not limited to, palmitic acid, butyric acid, caproic acid, caprylic acid, capric acid, stearic acid, lauric acid, myristic acid, arachic acid, myristoleic acid, palmitoleic acid, rapeseed oleic acid, linoleic acid or linolenic acid.
According to a particular embodiment of the invention, the composition comprises a food composition or a pharmaceutical composition.
According to a specific embodiment of the present invention, in the present invention, the food composition is a fermented dairy product, a cheese, a milk-containing drink, a solid drink, milk powder, or the like; preferably, the milk powder is an infant formula.
In another aspect, the invention also provides the use of a combination of palmitic acid glyceride and alpha-lactalbumin and/or beta-casein in the manufacture of a composition for improving or promoting magnesium absorption in an infant, wherein the Sn-2 palmitic acid in the palmitic acid glyceride comprises more than 35%, preferably more than 40%, more preferably more than 46% of the total palmitic acid content, calculated as palmitic acid;
the alpha-lactalbumin content represents more than 7% of the total protein content and/or the beta-casein content represents more than 13.5% of the total protein content.
According to a specific embodiment of the present invention, preferably, the content of Sn-2 palmitic acid in the palmitic acid glyceride is 52% or more, more preferably 60% or more, of the total palmitic acid content.
According to a particular embodiment of the invention, preferably, the alpha-lactalbumin content represents 7% to 30%, preferably 10% to 25% of the total protein content.
According to a particular embodiment of the invention, preferably, the beta-casein content represents between 15% and 40%, preferably between 17% and 30% of the total protein content.
The invention provides a novel application of palmitic acid glyceride, a combination of palmitic acid glyceride and alpha-lactalbumin and/or beta-casein in improving and promoting magnesium absorption of human body. Magnesium is the main cation in human cells, is concentrated in mitochondria, is inferior to potassium and phosphorus, is inferior to sodium and calcium in extracellular fluid, and is an essential substance for basic biochemical reactions of various cells in vivo. The combination of the palmitic acid glyceride and the alpha-lactalbumin and/or beta-casein can promote the absorption of magnesium by infants, and can be used as an infant milk powder additive to promote the height increase of infants.
Detailed Description
The technical solutions of the present invention will be described in detail below in order to clearly understand the technical features, objects, and advantages of the present invention, but the present invention is not limited to the practical scope of the present invention.
In the present invention, unless otherwise specified, wherein:
the term "glyceryl palmitate" means an acylglycerol having a glyceryl moiety to which at least one palmitic acid is attached, and may be selected from mono-, di-and tri-esters, wherein the glyceryl moieties of the di-and tri-esters may also have other fatty acid moieties attached thereto.
The term "Sn-2 palmitic acid" refers to palmitic acid attached to the Sn-2 position on a glyceryl portion of a fat.
The term "Sn-2 glyceryl palmitate" refers to fatty acid glycerides with palmitic acid attached to the Sn-2 position of the glyceryl moiety, and may be selected from the group consisting of Sn-2 monoglycerides, Sn-2 diglycerides and Sn-2 triglycerides; wherein, any fatty acid can be connected to the Sn-1 position and/or the Sn-3 position on the glyceryl in the Sn-2 palmitic acid diglyceride and the Sn-2 palmitic acid triglyceride, and the fatty acid comprises, but is not limited to, palmitic acid, butyric acid, caproic acid, caprylic acid, capric acid, stearic acid, lauric acid, myristic acid, arachic acid, myristoleic acid, palmitoleic acid, rapeseed oleic acid, linoleic acid, linolenic acid and the like.
The term 'alpha-lactalbumin' is a protein extracted from milk, has the characteristics of high nutritional value, easy digestion and absorption, multiple active ingredients and the like, and is one of high-quality protein supplements for human bodies.
The term "beta-casein" is a phosphorylated protein synthesized by mammary acinar epithelial cells and is widely found in the milk of mammals (cows, yaks, goats, horses, rabbits, etc.) and humans.
The ratio of the Sn-2 palmitic acid in the palmitic acid glyceride in the total palmitic acid content is calculated as follows:
(the number of palmitic acid groups in the Sn-2 position ÷ the number of all palmitic acid groups in the palmitic acid glyceride) × 100%
Calculated by palmitic acid, the proportion of Sn-2-palmitic acid in the formula in the content of all palmitic acid is calculated as follows:
(the number of the palmitic acid groups in the Sn-2 position divided by the number of all the palmitic acid groups in the formula) x 100%
The raw material sources are as follows:
the raw milk is from Yili own pasture
Skimmed milk powder and whey protein powder were purchased from Heng Natural Co, New Zealand
Desalted whey powder purchased from virio, Finland
Alpha-lactalbumin powder and beta-casein powder from Denmark Arara
Oil and fat raw materials such as OPO structure fat, corn oil, soybean oil, high oleic acid sunflower seed oil, etc. are purchased from Haja Jiali company
Galacto-oligosaccharides syrup and fructo-oligosaccharides were purchased from Quantum Kogaku.
Example 1
This example provides a formula prepared according to the formula in table 1.
Table 1 formulation of example 1
TABLE 2 ingredients contained in the Complex Nutrients
| Components | The content of the milk powder is converted into per hundred grams |
| Vitamin A (mu gRE) | 400 |
| Vitamin D (mug) | 8.3 |
| Vitamin E (mg alpha-TE) | 7.1 |
| Vitamin K1(μg) | 75 |
| Vitamin B1(μg) | 560 |
| Vitamin B2(μg) | 620 |
| Vitamin B6(μg) | 430 |
| Vitamin B12(μg) | 1.6 |
| Nicotinic acid (ug) | 4100 |
| Folic acid (mug) | 75 |
| Pantothenic acid (ug) | 2750 |
| Vitamin C (mg) | 65 |
| Biotin (ug) | 15 |
| Sodium (mg) | 140 |
| Potassium (mg) | 394 |
| Copper (mug) | 340 |
| Magnesium (mg) | 34 |
| Iron (mg) | 4.9 |
| Zinc (mg) | 3.9 |
| Manganese (ug) | 40.1 |
| Calcium (mg) | 370 |
| Phosphorus (mg) | 225 |
| Iodine (ug) | 63 |
| Chlorine (mg) | 317 |
| Selenium (mug) | 14.7 |
Table 3 table comparing contents of main nutrients in example 1 and comparative example 1
The formula milk powder is produced according to the following steps:
(1) according to the formula in table 1, raw milk, skim milk powder, lactose, whey protein powder (purity 70 wt.%), desalted whey powder (purity 12 wt.%), alpha-whey protein powder (purity 77 wt.%), OPO structure fat, high oleic sunflower seed oil, corn oil, soybean oil, galacto-oligosaccharide syrup (purity 57 wt.%), fructo-oligosaccharide (chicory source), beta-casein, soybean lecithin, choline chloride, compound nutrients (the components are shown in table 2) and other raw materials are uniformly mixed, and impurities are removed by a filter screen of a mixed material to obtain a material after impurity removal;
(2) homogenizing the material after impurity removal at 55-60 deg.C under 120bar to obtain homogenized material, and cooling to below 20 deg.C;
(3) concentrating the material to obtain concentrate with dry matter content of 50-52%;
(4) sterilizing the concentrate at 88-90 deg.C for 25 s to obtain sterilized material, and temporarily storing in a concentrated milk balance tank;
(5) preheating the sterilization material in a thick milk balance tank to 60-70 ℃ by a scraper preheater, filtering by a filter with the aperture of 1mm, pumping into a drying tower by a high-pressure pump for spray drying, wherein the air inlet temperature is 165-180 ℃, the air exhaust temperature is 83-96 ℃, the pressure of the high-pressure pump is 160-210 bar, and the negative pressure of the tower is about-5 mmWG, so as to obtain powder;
(6) further drying the powder material by a first-stage fluidized bed to obtain dry powder; dry mixing the dry powder with DHA and ARA at 25-30 deg.C by a secondary fluidized bed to obtain mixed powder;
(7) and (3) sieving the mixed powder by using a vibrating screen to obtain the formula milk powder 1 with uniform particles, and filling nitrogen for packaging.
In formula 1 prepared in this example, Sn-2 palmitic acid was 46.3% of all palmitic acid content by weight; alpha-lactalbumin accounted for 15.7% of the total protein, beta-casein accounted for 20.7% of the total protein, as shown in table 3. Raw milk, high oleic sunflower oil, corn oil, soybean oil, etc. also contribute some palmitic acid, and thus the percentage of Sn-2 palmitic acid in the raw material providing Sn-2 palmitic acid is higher than 46.3%.
Comparative example 1
The present comparative example provides a formula milk powder, which is prepared by the following steps.
(1) Mixing whole milk powder, skimmed milk powder, lactose, whey protein powder (purity 80 wt.%), desalted whey powder (purity 12 wt.%), OPO structure fat, high-oleic sunflower seed oil, corn oil, soybean oil, rapeseed oil, galacto-oligosaccharide syrup (purity 57 wt.%), fructo oligosaccharide (from chicory), soybean phospholipid, choline chloride and compound nutrients (the components are shown in Table 5) uniformly according to the formula in Table 4, and removing impurities from the mixed material by using a filter screen to obtain a material after impurity removal;
(2) homogenizing the material after impurity removal at 55-60 deg.C under 120bar to obtain homogenized material, and cooling to below 20 deg.C;
(3) concentrating the material to obtain concentrate with dry matter content of 50-52%;
(4) sterilizing the concentrate at a temperature of above 88 deg.C for 25 s to obtain sterilized material, and temporarily storing in a concentrated milk balance tank;
(5) preheating the sterilization material in a thick milk balance tank to 60-70 ℃ by a scraper preheater, filtering by a filter with the aperture of 1mm, pumping into a drying tower by a high-pressure pump for spray drying, wherein the air inlet temperature is 165-180 ℃, the air exhaust temperature is 83-96 ℃, the pressure of the high-pressure pump is 160-210 bar, and the negative pressure of the tower is about-5 mmWG, so as to obtain powder;
(6) further drying the powder material by a first-stage fluidized bed to obtain dry powder;
(7) dry mixing the dry powder with DHA and ARA at 25-30 deg.C by a secondary fluidized bed to obtain mixed powder;
(8) and (3) sieving the mixed powder by using a vibrating screen to obtain formula milk powder A with uniform particles, and filling nitrogen for packaging.
In formula a, Sn-2 palmitic acid accounted for 10.3%, α -lactalbumin accounted for 6.6%, and β -casein accounted for 13.4% of total protein, based on the weight of palmitic acid, as shown in table 3.
Table 4 formulation of comparative example 1
| Components | Dosage (kg) |
| Whole milk powder | 230 |
| Defatted milk powder | 100 |
| Lactose | 305 |
| Whey protein powder (purity 80 wt.%) | 50 |
| Desalted whey powder (purity 12 wt.%) | 170 |
| OPO structural fat | 100 |
| High oleic sunflower oil | 40 |
| Corn oil | 30 |
| Soybean oil | 70 |
| Rapeseed oil | 60 |
| Galacto-oligosaccharide syrup (purity 57 wt.%) and | 45 |
| fructo-oligosaccharide (chicory source) | 10 |
| Soybean lecithin | 1.4 |
| Choline chloride | 0.9 |
| DHA | 6 |
| ARA | 6 |
| Compound nutrient | 13.4 |
TABLE 5 ingredients contained in the Compound Nutrients
Example 2
This example provides an infant formula that improves or promotes magnesium absorption, wherein the formula provides, per hundred grams of final product: the energy is 2100KJ, the protein is 10.7g (wherein, the alpha-lactalbumin is 1.5g, the beta-casein is 2.4g), the fat is 27g, the carbohydrate is 51g, the linoleic acid is 4.3g, the alpha-linolenic acid is 450mg, the choline is 85mg, and the taurine is 40 mg;
the feed also contains vitamins such as vitamin A, vitamin D, vitamin E, vitamin B1, vitamin B2, vitamin B6, vitamin B12 and the like, and trace elements such as calcium, iron, zinc, magnesium and the like, wherein the contents of the vitamins and the trace elements meet the standard requirements of GB10765 national standard infant formula food for food safety or GB10766 national standard infant formula food for food safety or GB10767 national standard infant formula food for food safety; in particular, the content of palmitic acid in the Sn-2 position accounts for 36% of the total palmitic acid. The process for preparing the formula provided in this example is the same as in example 1.
Example 3
This example provides an infant formula that improves or promotes magnesium absorption, wherein the formula provides, per hundred grams of final product: the energy is 2100KJ, the protein is 10.7g (wherein, the alpha-lactalbumin is 1.8g, the alpha-casein is 2.4g), the fat is 27g, the carbohydrate is 51g, the linoleic acid is 4.3g, the alpha-linolenic acid is 450mg, the choline is 85mg, and the taurine is 40 mg;
simultaneously contains vitamins such as vitamin A, vitamin D, vitamin E, vitamin B1, vitamin B2, vitamin B6, vitamin B12 and the like, and trace elements such as calcium, iron, zinc, magnesium and the like, wherein the contents of the vitamins and the trace elements meet the standard requirements of GB10765 national standard infant formula food for food safety or GB10766 national standard larger infant formula food for food safety or GB10767 national standard infant formula food for food safety; in particular, the content of palmitic acid in the Sn-2 position accounts for 47% of the total palmitic acid. The process for preparing the formula provided in this example is the same as in example 1.
Example 4
This example provides an infant formula that improves or promotes magnesium absorption, wherein the formula provides, per hundred grams of final product: the energy is 2100KJ, protein 11g (wherein, alpha-lactalbumin is 2.0g, beta-casein is 3.5g), fat 27g, carbohydrate 51g, linoleic acid 4.3g, alpha-linolenic acid 450mg, choline 85mg and taurine 40 mg; simultaneously contains vitamins such as vitamin A, vitamin D, vitamin E, vitamin B1, vitamin B2, vitamin B6, vitamin B12 and the like, and trace elements such as calcium, iron, zinc, magnesium and the like, wherein the contents of the vitamins and the trace elements meet the standard requirements of GB10765 national standard infant formula food for food safety or GB10766 national standard larger infant formula food for food safety or GB10767 national standard infant formula food for food safety; in particular, the content of palmitic acid in the Sn-2 position accounts for 61% of the total palmitic acid. The process for preparing the formula provided in this example is the same as in example 1.
Clinical experimental method and experimental results:
the feeding effect of the formula of example 1 was compared to the formula of comparative example 1 in a random control design.
1. Grouping of subjects:
infants in need of inclusion were screened by recruiting screening questionnaires by pediatricians or trained researchers. Written informed consent was obtained from the mother prior to study entry.
1.1 inclusion criteria
And (3) full-term infants: the gestational week is more than or equal to 37 weeks;
birth weight: 2.5kg-4 kg;
normal pregnancy, delivered baby (including cesarean);
healthy, Apgar score > 7 after birth for 5-10 minutes;
age: < 15 days.
1.2 exclusion criteria
Infants with any of the following characteristics were excluded:
congenital malformations or chromosomal disorders detected at birth and of clinical significance;
patients with disease requiring mechanical ventilation or medication within one week after birth (infant jaundice patients who do not include blue light therapy);
those who affect feeding or metabolism due to suspected or unknown metabolic factors or due to physical defects;
twins or multiple births.
1.3 Experimental groups
Selecting full-term infants of 0-6 months as study objects, wherein the breast milk of the infants is sufficient after birth, and mothers are willing to basically feed the full-term infants to the full-term infants of 6 months as a breast milk group; the breast feeding can not be carried out, the feeding amount of the infant formula fed by the infant formula is determined to be more than or equal to 250mL/d at the age of 1-15 days, and the infant formula is randomly divided into a test group (fed with the formula of example 1) and a control group (fed with the formula of comparative example 1). The number of people in each group is not less than 5.
2. Intervention study method
Baseline (postnatal day 15) surveys and sample collections were conducted on enrolled infants, followed by continuous feeding for 6 months, during which time the subject was followed by visits by the project investigator at 4, 6, 8, 16, and 24 weeks after the start of feeding. The basic population sociology, magnesium absorption and utilization and growth and development of the infants are investigated.
3. Results of clinical experiments
3.1 basic demographic sociological conditions of infants in different experimental groups
The findings of the infants in the three experimental groups were compared: the social and demographic distributions of the test group, the breast-milk group and the control group are similar, except that the father working condition, the highest parental school calendar and the family income of the infants of the test group and the breast-milk group are slightly different, but the existing documents and reports for comparing and researching the breast-feeding and the formula-feeding of the infants generally show the differences, so the differences do not hinder or influence the comparison of the research results of the experiment. In addition, as shown in table 6: the gender ratio of the three groups of infants was not significantly different; the vaginal delivery rate of the breast milk group was higher than that of the test group and the control group, and there was no difference between the vaginal delivery rates of the test group and the control group; the T-test p-values for the breast milk group or control and test group data are also provided in table 6, with p-values < 0.05 indicating statistical differences and p-values < 0.01 indicating significant statistical differences.
TABLE 6 infant gender and delivery modality configuration
| Breast milk group | Test set | Control group | ||
| Gender of infant | For male | 36 persons (63.2%) | 33 persons (56.9%) | 29 persons (49.2%) |
| Woman | 21 persons (36.8%) | 25 persons (43.1%) | 30 persons (50.9%) | |
| P | 0.493 | 0.401 | ||
| Infant delivery method | Vaginal delivery | 37 persons (66.1%) | 21 persons (37.5%) | 15 persons (25.4%) |
| Caesarean section | 19 persons (33.9%) | 35 persons (62.5%) | 44 persons (74.6%) | |
| P | 0.003 | 0.163 |
3.2 absorption and utilization of magnesium by infants of different experimental groups
Bioavailability (biavallability) is used in the fields of pharmacology, nutrition and environmental science. In nutrition, it refers to the degree and rate at which the nutrients of ingested food are absorbed and utilized by the circulatory system (systemic circulation) of the human body.
If the magnesium level of the food is fixed, the digestibility of the magnesium can be judged according to the magnesium level of the feces, and the biological utilization, namely the absorption rate, of the magnesium is indirectly reflected. That is, the higher the fecal magnesium is discharged, the lower the digestion utilization rate is, and vice versa.
In this example, the magnesium content in the feces discharged from the breast-milk group, test group and control group infants at baseline (day 15 after birth), week 6, week 16 and week 24 was measured and the results are shown in Table 7. Where each data is represented in the median (25 th percentile, 75 th percentile). The magnesium content of the feces discharged by each group of infants at each time point is arranged from low to high, the "middle number" represents the magnesium content of the feces discharged by the infants arranged at the middle position at each time point, the "25 th percentile" represents the magnesium content of the feces discharged by the infants arranged at the position (the group number is multiplied by 25%) at each time point, and the "75 th percentile" represents the magnesium content of the feces discharged by the infants arranged at the position (the group number is multiplied by 75%) at each time point.
TABLE 7 magnesium content in infant faeces (median (P25, P75), mg/g) at different time points
Indicates significant difference, P < 0.05.
As can be seen from table 7, by adjusting the difference between the baseline content and the magnesium intake of the infant from milk powder or breast milk in the three groups, the total fecal magnesium content in the test group was lower than that in the control group and the breast milk group. The time variation trend of the content of the magnesium in the feces of the test group is statistically different from that of the control group and the breast milk group; this shows that the formula milk powder of the invention is helpful for improving the digestion, absorption and biological utilization of magnesium for infants.
Meanwhile, the test group and the control group are subjected to pure artificial feeding subgroup analysis, and after the two groups of baseline content and the magnesium intake of the infant from the milk powder are adjusted, the content of the whole excrement magnesium of the test group is still lower than that of the control group (table 8), and the formula milk powder is further proved to be helpful for improving the digestion, absorption and biological utilization of the infant on magnesium.
TABLE 8 magnesium content in feces of pure artificially fed subgroup (median (P25, P75), mg/g)
Represents significant difference, P < 0.05; indicates that the difference is very significant, P < 0.01.
3.3 baby physical examination
60% -65% of magnesium in the human body is located in bones. The content of magnesium in bones is second to that of calcium and phosphorus, is an essential element for maintaining the structure and the function of bone cells, and has the functions of maintaining and promoting the growth of bones and teeth. The quality of the skeletal development of the organism can be reflected on the constitution of the physique of the organism, and the indexes for measuring the physique comprise a Z scoring method and the like. The Z score is calculated using the standard formula: and Z score is (physical index actual measurement value-physical index reference value median)/physical index reference value standard deviation. The Z scoring method eliminates the influence of factors such as age, sex, height and the like, so the evaluation result is more accurate and objective.
A comparison between the 24 week old age-specific length Z score (HAZ) scores and the distribution of HAZ scores for the test group and the control group in the purely artificially fed subgroup is shown in table 9 and table 10. The HAZ score of the test group was significantly higher than the control group (table 9); there was also a statistical significance for the difference in the HAZ score distribution between the test and control groups (Table 10), with the proportion of HAZ >1 in the test group being higher than in the control group, while the proportion of HAZ < -1 is lower than in the control group.
The results show that the body length of the infant in the test group is increased more quickly than that of the infant in the control group, the development condition of the body skeleton is better, and meanwhile, the formula milk powder of the invention promotes the digestion, absorption and biological utilization of magnesium of the infant.
TABLE 9Z score for infants fed purely artificially (median (P25, P75))
| Test set | Control group | ||
| HAZ | 0.2(-0.78,1.18) | -0.2(-0.91,0.62) | |
| p value | 0.027 |
TABLE 10 pure Artificial feeding subgroup development Z score distribution N (%)
| Test set | Control group | ||
| HAZ | ＜-1 | 26(17.3) | 41(23.6) |
| -1～1 | 78(52.0) | 100(57.5) | |
| 1～2 | 26(17.3) | 26(14.9) | |
| ＞2 | 20(13.3) | 7(4.0) | |
| P | 0.013 |
It should be understood that the above examples are only for clarity of illustration and are not intended to limit the embodiments. Other variations and modifications will be apparent to persons skilled in the art in light of the above description. And are neither required nor exhaustive of all embodiments. And obvious variations or modifications therefrom are within the scope of the invention.
Claims (10)
1. Use of a palmitic acid glyceride in the manufacture of a composition for improving or promoting magnesium absorption in the human body, wherein the content of Sn-2 palmitic acid in the palmitic acid glyceride is 35% or more, preferably 40% or more, more preferably 46% or more of the total palmitic acid content, calculated as palmitic acid.
2. Use according to claim 1, wherein the palmitic acid in the Sn-2 position of the palmitic acid glyceride is present in an amount of at least 52%, preferably at least 60%, based on palmitic acid.
3. Use according to claim 1 or 2, wherein the Sn-2 glyceryl palmitate comprises one or more of a Sn-2 triglyceride palmitate, a Sn-2 diglyceride palmitate and a Sn-2 monoglyceride;
wherein, the Sn-1 position and/or the Sn-3 position on the glyceryl in the Sn-2 palmitic acid diglyceride and the Sn-2 palmitic acid triglyceride can be connected with any fatty acid, including palmitic acid, butyric acid, caproic acid, caprylic acid, capric acid, stearic acid, lauric acid, myristic acid, arachic acid, myristoleic acid, palmitoleic acid, rapeseed oleic acid, linoleic acid or linolenic acid.
4. Use according to any one of claims 1-3, wherein the composition comprises a food composition or a pharmaceutical composition.
5. Use according to claim 4, wherein the food composition is a fermented dairy product, a cheese, a milk-containing beverage, a solid beverage or a powdered milk; preferably, the milk powder is an infant formula.
6. Use of a combination of palmitic acid glycerides, wherein Sn-2 palmitic acid is present in the palmitic acid glycerides in an amount of more than 35%, preferably more than 40%, more preferably more than 46% of the total palmitic acid content, calculated as palmitic acid, and alpha-lactalbumin and/or beta-casein, for the manufacture of a composition for improving or promoting magnesium absorption in an infant;
the alpha-lactalbumin content represents more than 7% of the total protein content and/or the beta-casein content represents more than 13.5% of the total protein content.
7. Use according to claim 6, wherein the palmitic acid in the Sn-2 position of the palmitic acid glyceride is present in an amount of at least 52%, preferably at least 60%, based on palmitic acid.
8. Use according to claim 6, wherein the alpha-lactalbumin content is between 7% and 30% of the total protein content, preferably between 10% and 25%.
9. Use according to claim 6, wherein the beta-casein content is between 15% and 40%, preferably between 17% and 30% of the total protein content.
10. The use according to any one of claims 6-9, wherein the composition comprises a food composition and a pharmaceutical composition; the food composition is a fermented dairy product, a cheese, a milk-containing beverage, a solid beverage or milk powder; preferably, the milk powder is an infant formula.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111431476.7A CN114145458A (en) | 2021-11-29 | 2021-11-29 | Application of palmitic acid glyceride in preparing composition for improving or promoting magnesium absorption of human body |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111431476.7A CN114145458A (en) | 2021-11-29 | 2021-11-29 | Application of palmitic acid glyceride in preparing composition for improving or promoting magnesium absorption of human body |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114145458A true CN114145458A (en) | 2022-03-08 |
Family
ID=80784306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111431476.7A Pending CN114145458A (en) | 2021-11-29 | 2021-11-29 | Application of palmitic acid glyceride in preparing composition for improving or promoting magnesium absorption of human body |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114145458A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006225356A (en) * | 2005-02-21 | 2006-08-31 | Natural Group Honsha:Kk | Magnesium absorption promoter and magnesium supplement |
| CN103906435A (en) * | 2011-10-18 | 2014-07-02 | 雀巢产品技术援助有限公司 | Composition for use in the promotion of magnesium absorption and/or magnesium retention |
| CN110122595A (en) * | 2019-05-31 | 2019-08-16 | 江南大学 | A kind of human milk rouge substitution oil/fat composition |
| CN111227044A (en) * | 2019-11-20 | 2020-06-05 | 内蒙古伊利实业集团股份有限公司 | Dairy product, preparation method and medical application thereof |
-
2021
- 2021-11-29 CN CN202111431476.7A patent/CN114145458A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006225356A (en) * | 2005-02-21 | 2006-08-31 | Natural Group Honsha:Kk | Magnesium absorption promoter and magnesium supplement |
| CN103906435A (en) * | 2011-10-18 | 2014-07-02 | 雀巢产品技术援助有限公司 | Composition for use in the promotion of magnesium absorption and/or magnesium retention |
| CN110122595A (en) * | 2019-05-31 | 2019-08-16 | 江南大学 | A kind of human milk rouge substitution oil/fat composition |
| CN111227044A (en) * | 2019-11-20 | 2020-06-05 | 内蒙古伊利实业集团股份有限公司 | Dairy product, preparation method and medical application thereof |
| CN112823647A (en) * | 2019-11-20 | 2021-05-21 | 内蒙古伊利实业集团股份有限公司 | Application of composition in improving or promoting growth of infant |
Non-Patent Citations (6)
| Title |
|---|
| 杨普煜等: "Sn-2棕榈酸酯对婴幼儿健康的促进作用", 《食品科学技术学报》 * |
| 杨普煜等: "Sn-2棕榈酸酯对婴幼儿健康的促进作用", 《食品科学技术学报》, no. 04, 16 July 2018 (2018-07-16), pages 41 - 45 * |
| 王强等: "Sn-2位棕榈酸结构脂制备及其对婴儿生理功能研究进展", 《食品研究与开发》 * |
| 王强等: "Sn-2位棕榈酸结构脂制备及其对婴儿生理功能研究进展", 《食品研究与开发》, no. 19, 10 October 2017 (2017-10-10), pages 220 - 225 * |
| 韩瑞丽;马健;张佳程;生庆海;: "牛乳脂肪甘油三酯中sn-2位脂肪酸组成的分析" * |
| 韩瑞丽;马健;张佳程;生庆海;: "牛乳脂肪甘油三酯中sn-2位脂肪酸组成的分析", 乳业科学与技术, no. 02, pages 71 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111227045B (en) | Application of dairy product in promoting growth of length of mammal | |
| DE3856214T2 (en) | Diet compositions and methods of using bile acid activated lipase | |
| EP1976397B1 (en) | Infant immunological formula | |
| US12302934B2 (en) | Nutritional formula | |
| CN104351356A (en) | Novel fourth-generation infant formula and preparation method thereof | |
| CN102524422B (en) | Infant formula milk powder containing alpha-lactalbumin and lactoferrin and preparation method for infant formula milk powder | |
| TW200744573A (en) | Use of dha and ara in the preparation of a composition for preventing or treating obesity | |
| EA011075B1 (en) | Dry powdered milk formula | |
| CN111919889A (en) | Mother-emulsified infant formula goat milk powder capable of improving immunity and preparation method thereof | |
| CN114145346A (en) | Food composition, application of food composition in improving or promoting magnesium absorption and infant formula milk powder | |
| CN114223721A (en) | Application of palmitic acid glyceride in improving or promoting protein absorption of infants | |
| CN108157512A (en) | A formula milk powder for strengthening the gastrointestinal function of infants aged 6-12 months | |
| CN115500391B (en) | Fatty acid ester composition containing LPLn/OPLn | |
| CN115500393B (en) | Fatty acid ester composition containing OPLa triglyceride | |
| CN114145458A (en) | Application of palmitic acid glyceride in preparing composition for improving or promoting magnesium absorption of human body | |
| CN108882745B (en) | Lipid composition and use thereof | |
| CN111227046B (en) | Application of dairy product in improving infant intestinal SIgA level | |
| US20160030466A1 (en) | Use of specific carbohydrate systems during pregnancy for improving bone development and formation and/or for improving cognitive and cns development in offspring | |
| CN120225074A (en) | Myo-Inositol and Prevention of Accelerated Growth | |
| CN117652577A (en) | Infant formula milk powder capable of affecting brain hippocampus protein expression and preparation method thereof | |
| Gašper et al. | Cow vs goat milk in infant’s nutrition: What is better? Review | |
| RU2440767C1 (en) | Sterilised dairy product based on goat milk for pregnant and nursing women alimentation | |
| US20060286199A1 (en) | Method and composition for increasing omega-3 lipid in milk | |
| CN117481206A (en) | Infant formula milk powder capable of improving spatial learning and memory capacity and preparation method thereof | |
| US20230233588A1 (en) | Compositions comprising myo-inositol and their use in the prevention of post partum haemorrhage (pph) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Ye Wenhui Inventor after: Shao Jianbo Inventor after: Liu Biao Inventor after: Zhou Mingqiao Inventor before: Ye Wenhui Inventor before: Liu Biao Inventor before: Zhou Mingqiao |
|
| CB03 | Change of inventor or designer information | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220308 |
|
| RJ01 | Rejection of invention patent application after publication |